The ABCB6 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the SK-HEP-1 human hepatic adenocarcinoma cell line. This product provides loss-of-function disruption of the ABCB6 gene, which encodes a mitochondrial outer membrane transporter essential for porphyrin metabolism and heme biosynthesis. The polyclonal composition yields a diverse array of edited alleles, enabling functional interrogation without clonal selection. This knockout model is tailored for dissecting ABCB6-dependent pathways in liver cancer, where porphyrin trafficking and heme homeostasis intersect with malignancy and drug sensitivity.
SK-HEP-1 cells were originally derived from ascitic fluid of a patient with liver adenocarcinoma and display a distinctive endothelial and epithelial phenotype. Widely utilized as a model for hepatocellular carcinoma biology, angiogenesis, and xenobiotic metabolism, this cell line retains a functional complement of cytochrome P450 enzymes and drug transporters. Consequently, SK-HEP-1 offers a physiologically relevant system for studying mitochondrial functions and ABC transporter networks in the context of hepatic drug metabolism and tumor oxidative stress.
ABCB6 resides on the mitochondrial outer membrane and mediates the rate-limiting import of coproporphyrinogen III into the intermembrane space, where CPOX and PPOX catalyze its conversion to protoporphyrin IX for heme synthesis by FECH. ABCB6 is transcriptionally activated by GATA1 and NRF2 and acts downstream of HIF1A and HIF-2??. Heme, the biosynthetic product, governs cytochrome c maturation, HMOX1 expression, beta-globin synthesis, and iron-sulfur cluster assembly. ABCB6 functions as a homodimer and associates with the TOM complex and mitochondrial chaperones; its secondary efflux capability may modulate intracellular drug distribution and resistance.
In SK-HEP-1 cells, ABCB6 knockout abolishes coproporphyrinogen III import, causing porphyrin intermediate accumulation, heme depletion, and hemoprotein dysfunction. Because heme is an obligate cofactor for drug-metabolizing cytochrome P450s and antioxidant enzymes, knockout cells are likely to show altered chemosensitivity??for instance, to doxorubicin, sorafenib, or cisplatin??and elevated mitochondrial oxidative stress. The model also mirrors aspects of porphyria cutanea tarda and dyschromatosis universalis hereditaria, offering a cellular system to examine heme-related pathologies in a liver adenocarcinoma background.
This knockout product supports investigations of porphyrin trafficking in liver adenocarcinoma, ABCB6-mediated chemoresistance, and mitochondrial heme homeostasis. Standard validation includes Western blotting for ABCB6 and RT-qPCR for heme biosynthetic genes; functional assays encompass mitochondrial porphyrin accumulation, cytochrome c oxidase activity, heme quantification, and cell viability following chemotherapy. Transcriptomic profiling by RNA-seq and flow cytometric analysis of mitochondrial mass and reactive oxygen species further enable pathway characterization. For further details, please contact Ascent Research.
